```html

Neuroleptic Malignant Syndrome (NMS)

Overview

Neuroleptic Malignant Syndrome (NMS) is a rare but life‑threatening reaction to antipsychotic (neuroleptic) drugs or, less commonly, to abrupt withdrawal of dopamine‑enhancing agents. It is characterized by a rapid onset of severe muscle rigidity, high fever, autonomic instability, and altered mental status.

Who it affects: NMS can develop in anyone taking dopamine‑blocking medications, most often adults receiving high‑potency antipsychotics for schizophrenia, bipolar disorder, or severe agitation. It has also been reported in children and adolescents, especially when atypical antipsychotics are used at high doses.

Prevalence: The incidence is low—estimated at 0.02 %–0.2 % of patients on typical (first‑generation) antipsychotics and <0.01 % on atypical (second‑generation) agents. Mortality historically ranged from 10 %–30 % but has dropped to <10 % with early recognition and modern intensive care (Mayo Clinic; WHO).

Symptoms

The classic tetrad—hyperthermia, muscle rigidity, autonomic dysregulation, and mental status change—appears within 24–72 hours of drug exposure, but onset can be delayed up to 2 weeks.

Core symptoms

• Fever – often > 38.5 °C (101.3 °F); can exceed 41 °C (105.8 °F) and become refractory to antipyretics.
• Severe “lead‑pipe” muscle rigidity – generalized, may cause painful decerebrate posturing.
• Autonomic instability – tachycardia, labile blood pressure, diaphoresis, tachypnea, and dysrhythmias.
• Altered mental status – confusion, agitation, delirium, or stupor; seizures may occur.

Additional clinical features

• Elevated serum creatine kinase (CK) > 1,000 IU/L (often > 5,000 IU/L) due to rhabdomyolysis.
• Myoglobinuria – dark‑colored urine, risk of acute kidney injury.
• Leukocytosis (white‑blood‑cell count > 11 × 10⁹/L).
• Metabolic acidosis, electrolyte disturbances (especially hyperkalemia).
• Respiratory failure from severe rigidity or aspiration.
• Rarely, cardiac arrhythmias, pulmonary embolism, or disseminated intravascular coagulation (DIC).

Causes and Risk Factors

NMS is an idiosyncratic reaction, not dose‑dependent, but several factors increase susceptibility.

Medication‑related triggers

• Typical antipsychotics – haloperidol, fluphenazine, chlorpromazine (higher risk).
• Atypical antipsychotics – risperidone, olanzapine, clozapine (lower but still possible).
• Dopamine‑depleting drugs – metoclopramide, promethazine, reserpine.
• Rapid dose escalation or parenteral administration – especially intramuscular or intravenous.
• Discontinuation of dopaminergic agents – levodopa withdrawal in Parkinson’s disease.

Patient‑related risk factors

• Young adult males (male‑to‑female ratio ≈ 2:1).
• History of NMS or severe adverse reactions to neuroleptics.
• Dehydration, electrolyte imbalance, or pre‑existing renal/hepatic disease.
• Concomitant use of serotonergic agents (e.g., SSRIs) that may potentiate dopamine blockade.
• High‑potency antipsychotic treatment for agitation or delirium in intensive‑care settings.

Diagnosis

There is no single laboratory test for NMS; diagnosis is clinical, based on recognized criteria (Levenson, DSM‑5, or ICD‑10). The most widely used are the Levenson criteria, requiring:

• Presence of major features: hyperthermia, rigidity, elevated CK, and autonomic instability.
• Or at least two major plus one minor feature (e.g., tachycardia, abnormal LFTs, leukocytosis).

Diagnostic work‑up

• **Complete blood count (CBC)** – leukocytosis.
• **Serum creatine kinase (CK)** – markedly elevated; serial measurements track response.
• **Comprehensive metabolic panel** – assess renal function, electrolytes, liver enzymes.
• **Urinalysis** – myoglobinuria (positive dipstick for blood without RBCs).
• **Electrocardiogram (ECG)** – tachyarrhythmias, QT prolongation.
• **Chest X‑ray** – evaluate for aspiration pneumonia.
• **MRI/CT** only if alternate neurologic causes are suspected (e.g., stroke, meningitis).

Because NMS mimics serotonin syndrome, malignant hyperthermia, severe infection, and catatonia, physicians must rule out these conditions while initiating treatment.

Treatment Options

Management is urgent, multidisciplinary, and usually requires intensive‑care unit (ICU) support.

Immediate steps

1. Discontinue the offending agent immediately.
2. Supportive care – aggressive cooling (ice packs, cooling blankets, antipyretics are adjunct only), intravenous fluids (30 mL/kg bolus, then maintenance), and electrolyte correction.
3. Monitoring – continuous cardiac, pulse‑ox, temperature, and urine output surveillance.

Specific pharmacologic therapies

• Dantrolene sodium (muscle relaxant) – 1 mg/kg IV bolus, repeat every 6 hours up to 10 mg/kg/day; reduces rigidity and heat production (Cleveland Clinic).
• Dopamine agonists – bromocriptine 2.5–5 mg PO/NG q6‑8 h or levodopa 100–200 mg PO q6 h; help restore dopaminergic tone.
• Anticholinergics – physostigmine is not routinely used; mild benefit reported with benztropine.
• Beta‑blockers – propranolol (if severe tachycardia) but avoid in patients with asthma or heart block.

Adjunctive measures

• **Renal protection** – forced diuresis or hemodialysis if acute kidney injury from rhabdomyolysis.
• **Airway management** – early intubation for severe rigidity or respiratory compromise.
• **Deep vein thrombosis prophylaxis** – pneumatic compression devices or low‑dose heparin.
• **Psychiatric liaison** – once the patient stabilizes, reassess the need for antipsychotic therapy and consider alternative agents (e.g., clozapine with caution).

Recovery timeline

Symptoms generally improve within 2–5 days after cessation of the trigger and initiation of therapy. CK levels may take 1–2 weeks to normalize. Full neurologic recovery is expected in the majority of patients, though residual cognitive deficits have been reported in up to 10 % of survivors.

Living with Neuroleptic Malignant Syndrome

For patients who have experienced NMS, ongoing care focuses on medication safety, monitoring, and psychosocial support.

Medication management

• Maintain a comprehensive medication list and share it with every prescriber.
• If antipsychotic therapy is still required, restart at the lowest possible dose after a symptom‑free interval of ≥ 2 weeks, preferably with an atypical agent that has a lower D₂ affinity.
• Consider non‑pharmacologic interventions** for psychosis or agitation (e.g., CBT, psychotherapy, structured environment).

Self‑monitoring & lifestyle

• Track body temperature daily for the first month after re‑initiation of any dopamine‑blocking drug.
• Stay well‑hydrated; avoid excessive alcohol or illicit substances that may alter thermoregulation.
• Engage in regular, moderate exercise—avoid extremes that could stress muscles.
• Educate family members on early warning signs (fever, rigidity, confusion).

Follow‑up care

• Schedule a follow‑up with psychiatry within 1 week of discharge, then monthly for the first 3 months.
• Repeat CK and renal panels 48 hours after discharge to confirm resolution.
• Consider a referral to a neuro‑rehabilitation specialist if residual motor weakness persists.

Prevention

Prevention hinges on prudent prescribing and early detection.

• Start low, go slow – begin with the smallest effective dose and titrate gradually.
• Avoid rapid switching between high‑potency antipsychotics or from oral to IM/IV routes.
• Screen for risk – document prior NMS, dehydration, or medical comorbidities before initiating neuroleptics.
• Hydration status – ensure adequate fluid intake, especially during fever or infection.
• Educate patients and caregivers about early symptoms.
• Use alternative therapies (e.g., mood stabilizers, psychotherapy) when feasible.

Complications

If NMS is not recognized promptly, morbidity can be severe.

• Rhabdomyolysis leading to acute kidney injury – may require dialysis.
• Cardiovascular collapse – arrhythmias, myocardial infarction, or heart failure.
• Respiratory failure – due to airway obstruction from rigidity or aspiration.
• Severe electrolyte abnormalities – hyperkalemia, hyponatremia, which can precipitate seizures.
• Multiorgan dysfunction syndrome (MODS) – especially in older adults.
• Death – historically 10–30 % mortality, now <10 % with prompt ICU care.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you or someone you are caring for experiences any of the following while taking an antipsychotic or dopamine‑blocking medication:

• High fever (≥ 38.5 °C / 101.3 °F) that does not respond to acetaminophen.
• Sudden, severe muscle stiffness that makes movement painful.
• Rapid heart rate (> 120 bpm) or blood pressure that spikes or drops dramatically.
• Confusion, agitation, delirium, or loss of consciousness.
• Dark, tea‑colored urine indicating possible myoglobinuria.
• Chest pain, shortness of breath, or difficulty breathing.

Early recognition saves lives. Do not wait for all symptoms to appear; a single major sign (e.g., fever + rigidity) warrants emergency evaluation.

---

Sources: Mayo Clinic, CDC, National Institutes of Health (NIH), World Health Organization (WHO), Cleveland Clinic, American Psychiatric Association, JAMA Neurology, British Journal of Psychiatry. All information is intended for educational purposes and does not replace professional medical advice.

```